MYOVライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (10 3月 2023 @ 06:01):

Stats
本日の出来高	2.26M
平均出来高	1.09M
時価総額	2.62B
EPS	$0 ( 2023-07-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.05
ATR14	$0.0590 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-10	Valente Nancy	Sell	3 673	Common Shares
2023-03-10	Valente Nancy	Sell	36 892	Stock Options (Right to Buy)
2023-03-10	Potter Myrtle S	Sell	3 673	Common Shares
2023-03-10	Potter Myrtle S	Sell	45 000	Stock Options (Right to Buy)
2023-03-10	Potter Myrtle S	Sell	58 608	Stock Options (Right to Buy)

INSIDER POWER
71.96
Last 100 transactions
Buy: 52 768 183 \| Sell: 8 648 674

ボリューム相関

長: 0.03 (neutral)

短: -0.75 (moderate negative)

Signal:(61.005) Neutral

Myovant Sciences Ltd 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Myovant Sciences Ltd 相関 - 通貨/商品

0.14
( neutral )

0.20
( neutral )

-0.23
( neutral )

0.37
( neutral )

0.06
( neutral )

0.01
( neutral )

Myovant Sciences Ltd 財務諸表

Annual	2022
収益:	$230.97M
総利益:	$179.42M (77.68 %)
EPS:	$-2.22

FY	2022
収益:	$230.97M
総利益:	$179.42M (77.68 %)
EPS:	$-2.22

FY	2021
収益:	$59.32M
総利益:	$57.35M (96.69 %)
EPS:	$-2.83

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.37

Financial Reports:

No articles found.

Myovant Sciences Ltd

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.